Gait Variability in Spinocerebellar Ataxia Assessed Using Wearable Inertial Sensors
Background Quantitative assessment of severity of ataxia‐specific gait impairments from wearable technology could provide sensitive performance outcome measures with high face validity to power clinical trials. Objectives The aim of this study was to identify a set of gait measures from body‐worn in...
Saved in:
Published in | Movement disorders Vol. 36; no. 12; pp. 2922 - 2931 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.12.2021
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 0885-3185 1531-8257 1531-8257 |
DOI | 10.1002/mds.28740 |
Cover
Summary: | Background
Quantitative assessment of severity of ataxia‐specific gait impairments from wearable technology could provide sensitive performance outcome measures with high face validity to power clinical trials.
Objectives
The aim of this study was to identify a set of gait measures from body‐worn inertial sensors that best discriminate between people with prodromal or manifest spinocerebellar ataxia (SCA) and age‐matched, healthy control subjects (HC) and determine how these measures relate to disease severity.
Methods
One hundred and sixty‐three people with SCA (subtypes 1, 2, 3, and 6), 42 people with prodromal SCA, and 96 HC wore 6 inertial sensors while performing a natural pace, 2‐minute walk. Areas under the receiver operating characteristic curves (AUC) were compared for 25 gait measures, including standard deviations as variability, to discriminate between ataxic and normal gait. Pearson's correlation coefficient assessed the relationships between the gait measures and severity of ataxia.
Results
Increased gait variability was the most discriminative gait feature of SCA; toe‐out angle variability (AUC = 0.936; sensitivity = 0.871; specificity = 0.896) and double‐support time variability (AUC = 0.932; sensitivity = 0.834; specificity = 0.865) were the most sensitive and specific measures. These variability measures were also significantly correlated with the scale for the assessment and rating of ataxia (SARA) and disease duration. The same gait measures discriminated gait of people with prodromal SCA from the gait of HC (AUC = 0.610, and 0.670, respectively).
Conclusions
Wearable inertial sensors provide sensitive and specific measures of excessive gait variability in both manifest and prodromal SCAs that are reliable and related to the severity of the disease, suggesting they may be useful as clinical trial performance outcome measures. © 2021 International Parkinson and Movement Disorder Society |
---|---|
Bibliography: | None. Funding agency Relevant conflicts of interest/financial disclosures J.M., M.E.G., and F.B.H. have a significant financial interest in APDM Wearable Technologies‐an ERT company, that may have a commercial interest in the results of this research and technology. F.B.H. also consults with Autobahn, Biogen, Pfizer, Medtronic, Neuropore, Sanofi, and Takeda. J.D.S. receives support as site principal investigator for a clinical trial with Biohaven Pharmaceuticals, and for service on the scientific advisory board of Cadent Therapeutics. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 0885-3185 1531-8257 1531-8257 |
DOI: | 10.1002/mds.28740 |